__

Proteonomix, Inc. (PROT) Plans European Investor Road Show

-Michael Cohen, Chairman and CEO, to Visit Several European Cities to Discuss Company’s Growth Plan and Future Outlook With Investors

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.

For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

Proteonomix’s Mission

The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.

We are primarily focused on developing therapies and products based upon the use of human stem cells and their derivatives with an initial focus on diabetes and cardiac diseases. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include but are not limited to cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.

About Proteonomix

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD).

StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

http://www.proteonomix.com/

__

UnitedHealthcare Offers New Health Plan in Chicago and Northwest Indiana

-“UnitedHealthcare Core” is a cost-effective alternative to traditional HMOs, with greater flexibility and non-network benefits

UnitedHealth Group (NYSE: UNH) has begun offering a new health plan option called “UnitedHealthcare Core” in Chicago and Northwest Indiana.

Core is an insurance product that enables health plan participants to reduce their out-of-pocket health care costs when they seek care within a designated provider network that includes 97 hospitals and more than 16,500 doctors in the Chicagoland area.

However, unlike a traditional HMO, Core plan participants may access care from doctors and hospitals outside the designated network, including UnitedHealthcare’s national network of providers that number more than 600,000 physicians and care professionals, 5,000 hospitals and 60,000 pharmacies. Plus, Core may be paired with a health savings account (HSA), which enables people to take advantage of pre-tax savings and save for future health care expenses. Core also covers preventive care services and visits to specialists without the need for written referrals.

In addition, plan participants have access to expanded programs and services including Care24®, UnitedHealthcare’s 24-hour nurse line, and the Healthy Pregnancy Program, a resource for expectant mothers, as well as online tools that help people make more informed health care decisions, take advantage of wellness programs, and identify UnitedHealth Premium® designated physicians and specialty care centers that consistently meet or exceed evidence-based quality and cost-efficient criteria.

Core is available to employers of all sizes. To date, more than 35,000 individuals are already enrolled in the plan.

UnitedHealthcare provides a full spectrum of consumer-oriented health benefits plans and services to individuals, public sector employers and businesses of all sizes, including more than half of the Fortune 100 companies.

The company organizes access to quality, affordable health care services on behalf of approximately 25 million individual consumers, contracting directly with more than 600,000 physicians and care professionals and 5,000 hospitals to offer them broad, convenient access to services nationwide.

www.unitedhealthcare.com

__

A.M. Best Assigns Rating to WellPoint, Inc.’s New Senior Unsecured Notes

A.M. Best Co. has assigned a debt rating of “bbb+” to $700 million 4.35% senior unsecured notes due 2020 and “bbb+” to $300 million 5.80% senior unsecured notes due 2040 recently issued by WellPoint, Inc. (WellPoint) (NYSE: WLP). The rating outlook is stable.

A.M. Best expects that the proceeds will be used for working capital and for general corporate purposes, which may include the repayment of short and long-term debt. The existing ratings of WellPoint and its subsidiaries are unchanged.

WellPoint’s debt to capital at June 30, 2010 was approximately 27%, up slightly from year-end 2009 as shareholders’ equity declined slightly due to WellPoint’s share repurchase program. A.M. Best expects WellPoint’s financial leverage to be at or below 30% at year-end 2010. EBIT interest coverage was 12 times at year-end 2009 and is expected to remain at or above 10 times for the full year 2010. Both the debt to capital ratio and the EBIT interest coverage are well within the guidelines for the rating.

WellPoint is well diversified geographically across business segments. Earnings and operational cash flows have been strong. The operating entities’ capitalization improved in 2009. WellPoint carries a significant amount of goodwill and other intangible assets on its balance sheet. However, A.M. Best does recognize that the company’s intangibles plus goodwill to equity ratio is in line with some of its peers.

The principal methodology used in determining these ratings is Best’s Credit Rating Methodology - Global Life and Non-Life Insurance Edition, which provides a comprehensive explanation of A.M. Best’s rating process and highlights the different rating criteria employed. Additional key criteria utilized include “A.M. Best’s Ratings & the Treatment of Debt.”

Founded in 1899, A.M. Best Company is a global full-service credit rating organization dedicated to serving the financial and health care service industries, including insurance companies, banks, hospitals and health care system providers.

www.ambest.com

__

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

____________________

Sign Up for our FREE Daily Stock Newsletter

____________________

 

 

Tags:

A.M. Best Co |  cardiovascular disease |  Michael Cohen |  NYSE:UNH |  NYSE:WLP |  OTC:PROT |  PROT.OB |  Proteoderm |  Proteonomix |  StromaCel |  StromalCel |  UNH |  United Health Group |  UnitedHealth Group |  WellPoint |  WLP